Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

CombiGene: Strategic consequences after CG01 - VH Corp

Lärkberget

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
* Implementing cost savings and new priorities
* New propositions from the main shareholder
* Our revised fair value estimate is SEK 8.27 (12.19) per share

In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again after reaching a return agreement with Spark Therapeutics. The company was also focused on developing the COZY programme for chronic pain. After evaluating the status of CG01, CombiGene decided to end the project and prioritise the COZY programme, with emphasis on the gene therapy COZY02. The company will also implement cost savings to prolong its financial runway. In Västra Hamnen’s webcast, CEO Peter Ekolind explained the reasons behind these decisions. Shortly after the webcast, the company’s largest shareholder proposed strategic changes, which shareholders will vote on in December. After a review, our estimated value is 8.27 SEK per share.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.